TREM1 shows significant enrichment in aggressive GBM subtypes and its inhibition functionally mediates anti-tumor effects by suppressing the glioma proneural-to-mesenchymal transition through modulation of the TLR4/PI3K/AKT/mTOR pathway. This evidence concerns the gene TLR4 and central nervous system cancer.